- Home
- ACIU vs BANX Comparison
ACIU vs BANX Comparison
Compare ACIU & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- BANX
- Stock Information
- Founded
- ACIU 2003
- BANX 2013
- Country
- ACIU Switzerland
- BANX United States
- Employees
- ACIU N/A
- BANX N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- BANX Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- BANX Finance
- Exchange
- ACIU Nasdaq
- BANX Nasdaq
- Market Cap
- ACIU 168.7M
- BANX 144.3M
- IPO Year
- ACIU 2016
- BANX N/A
- Fundamental
- Price
- ACIU $1.73
- BANX $20.23
- Analyst Decision
- ACIU Strong Buy
- BANX
- Analyst Count
- ACIU 2
- BANX 0
- Target Price
- ACIU $10.00
- BANX N/A
- AVG Volume (30 Days)
- ACIU 103.2K
- BANX 17.2K
- Earning Date
- ACIU 08-05-2025
- BANX 07-15-2025
- Dividend Yield
- ACIU N/A
- BANX 10.45%
- EPS Growth
- ACIU N/A
- BANX N/A
- EPS
- ACIU N/A
- BANX 2.35
- Revenue
- ACIU $32,014,254.00
- BANX $29,467,794.00
- Revenue This Year
- ACIU N/A
- BANX N/A
- Revenue Next Year
- ACIU $533.21
- BANX N/A
- P/E Ratio
- ACIU N/A
- BANX $8.45
- Revenue Growth
- ACIU 91.20
- BANX 2.73
- 52 Week Low
- ACIU $1.43
- BANX $17.99
- 52 Week High
- ACIU $4.98
- BANX $21.67
- Technical
- Relative Strength Index (RSI)
- ACIU 54.55
- BANX 52.39
- Support Level
- ACIU $1.60
- BANX $19.81
- Resistance Level
- ACIU $1.82
- BANX $20.36
- Average True Range (ATR)
- ACIU 0.10
- BANX 0.39
- MACD
- ACIU 0.01
- BANX -0.02
- Stochastic Oscillator
- ACIU 65.38
- BANX 49.41
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.